Mismatch negativity in tobacco-naïve cannabis users and its alteration with acute nicotine administration.

What Was Tested

Researchers studied Therapeutic nicotine (patch, non-peptide) in this randomized controlled trial publication.

The objective of this study was to compare tobacco-naïve cannabis users with individuals without a history of tobacco/cannabis use on the auditory mismatch negativity (MMN) event-related potential (ERP), a neural measure of auditory deviance detection which is diminished in SZ.

Why It Was Studied

Chronic cannabis use may interact with factors, such as age of onset of cannabis use, family history, and genetic factors, to elicit schizophrenia (SZ)-like symptoms, including sensory and cognitive deficits.

However, evidence of a relationship between cannabis use and cognitive impairment is confounded by concomitant use of tobacco.

Who Took Part

PubMed indexes the participants as teenagers, young adults and adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Therapeutic nicotine (patch, non-peptide) and who got the comparison, which limits bias.

As a double-blind Therapeutic nicotine (patch, non-peptide) study, the assignments were hidden from both participants and investigators until the end.

Some participants received a placebo instead of Therapeutic nicotine (patch, non-peptide), giving a reference point.

What Was Measured

PubMed files the paper under topics including Acoustic Stimulation, Auditory Perceptual Disorders, Case-Control Studies, Evoked Potentials, Auditory, Marijuana Abuse and Nicotine.

Author keywords: Auditory deviance detection, Cannabis, Event-related potential, MMN, Mismatch negativity and Schizophrenia.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Therapeutic nicotine (patch, non-peptide).

The publication is from 2015 (Pharmacology, biochemistry, and behavior), a journal based in United States.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.